Loading
DM4 is a maytansinoid payload released in a form that can cross membranes, giving mirvetuximab soravtansine a bystander effect that DM1 lacks.
DM4 (ravtansine or soravtansine) is attached through a hindered disulfide linker (sulfo-SPDB). After cleavage the payload is S-methylated inside the cell into a neutral, permeable form, so it can diffuse into neighbouring cells. Ocular toxicity (keratopathy, blurred vision) is the dose-limiting effect and is managed with steroid eye drops.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Mirvetuximab soravtansine.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Mitosis & the spindle assembly checkpoint.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Mitosis & the spindle assembly checkpoint.
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
Shares Mirvetuximab soravtansine, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).